IMAAVY® (nipocalimab-aahu) resources

Learn more about generalized myasthenia gravis (gMG) and IMAAVY

Discover what IMAAVY can do for you

Watch the video and speak to your healthcare provider today.

IMAAVY patient stories

Hear about the treatment experiences of Allison, a patient on IMAAVY.

IMAAVY patient stories

Hear about the treatment experiences of Ellen, a patient on IMAAVY.

Learn more about
IMAAVY from our clinical educators

Register for our webinar series and learn more about IMAAVY from our clinical educator experts. Ready to sign up?

Sign up now

Discover what IMAAVY can do for you

Watch the video and speak to your healthcare provider today.

Download the IMAAVY withMe Savings Program Web Flashcard

Learn about the IMAAVY withMe Savings Program and how it can help eligible patients save on out-of-pocket treatment costs.

Download

Download the IMAAVY withMe Affordability Brochure

Read about how IMAAVY withMe can help you find cost support options, regardless of your insurance type.

Download

Download the IMAAVY withMe Caregiver’s Guide to Self-Care

Follow these tips to help you care for yourself so that you can be a better caregiver for someone else.

Download

The support and resources provided by IMAAVY withMe are not intended to provide medical advice, replace a treatment plan you receive from your healthcare provider or nurse, or serve as a reason for you to start or stay on treatment.

Commonly asked questions about IMAAVY

You may be eligible for IMAAVY if you are 12 years of age and older and have generalized myasthenia gravis (gMG) that is antibody-positive (anti-acetylcholine receptor [AChR] or anti-muscle-specific tyrosine kinase [MuSK]). Talk to your healthcare provider to find out if IMAAVY is the right choice for you.

IMAAVY is
FDA
-approved to treat the broadest age range of gMG patients among approved FcRn blockers (adults and children 12 years of age and older with anti-AChR+ or anti-MuSK+ gMG).*

*It is not known if IMAAVY is safe and effective in children under 12 years of age.

As a neonatal fragment crystallizable receptor (FcRn) blocker, IMAAVY binds to FcRn to help reduce the amount of circulating immunoglobulin G (IgG) antibodies, including harmful anti-AChR and anti-MuSK antibodies, in your body.

Based on research from laboratory and/or clinical studies. The clinical significance of these findings is unknown.

See the science
behind IMAAVY

  • IMAAVY will be given to you by your healthcare provider through intravenous (IV) infusion into your vein
  • You will receive a starting dose of IMAAVY infusion lasting at least 30 minutes. Two weeks later you will receive your next dose of IMAAVY infusion lasting at least 15 minutes. Your following doses will be given every 2 weeks.

Your healthcare provider should monitor you for reactions to IMAAVY during the infusion and for 30 minutes after each infusion. If you have a reaction during your IMAAVY infusion, your healthcare provider may infuse IMAAVY more slowly, or give you medicine before your infusion, or stop your infusion if your reaction is severe.

If you miss a scheduled IMAAVY infusion, you should receive your next dose as soon as possible.

IMAAVY will be given to you by your healthcare provider through intravenous (IV) infusion into your vein.

  • You will receive a starting dose of IMAAVY infusion lasting at least 30 minutes. Two weeks later you will receive your next dose of IMAAVY infusion lasting at least 15 minutes. Your following doses will be given every 2 weeks
  • Your healthcare provider should monitor you for reactions to IMAAVY during the infusion and for 30 minutes after each infusion. If you have a reaction during your IMAAVY infusion, your healthcare provider may infuse IMAAVY more slowly, or give you medicine before your infusion, or stop your infusion if your reaction is severe
  • If you miss a scheduled IMAAVY infusion, you should receive your next dose as soon as possible

The most common side effects in people with gMG treated with IMAAVY include:

  • infection in parts of your body that you use for breathing (respiratory tract infection)
  • swelling in your hands, ankles, or feet (peripheral edema)
  • muscle spasms

If you have a reaction during your IMAAVY infusion, your healthcare provider may infuse IMAAVY more slowly, or give you medicine before your infusion, or stop your infusion if your reaction is severe.


IMAAVY can cause serious side effects, including:

  • Infections. IMAAVY may increase your risk of infections, including serious infections. If you have an infection, your healthcare provider will treat your infection or delay your infusion until your infection is gone. Tell your healthcare provider right away if you have any of the following infection symptoms:
    • fever
    • chills
    • shivering
    • cough
    • sore throat
    • fever blisters
    • burning when you urinate
    • trouble breathing
  • Allergic (hypersensitivity) reactions can happen during or up to a few weeks after your IMAAVY infusion. Tell your healthcare provider and get emergency medical help right away if you get any of these symptoms during or after your IMAAVY infusion:
    • a swollen face, lips, mouth, tongue, or throat
    • trouble swallowing or breathing
    • hives
    • itchy rash
    • chest pain or tightness
  • Infusion-related reactions. Tell your healthcare provider right away if you get any of these symptoms during or within a few days after your IMAAVY infusion:
    • headache
    • rash
    • nausea
    • fatigue
    • dizziness
    • chills
    • flu-like symptoms
    • redness of skin

These are not all of the possible side effects of IMAAVY. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Glossary

Autoimmune: Refers to a category of conditions in which the immune system mistakenly attacks the body's own organs or tissues. Myasthenia gravis (MG) is considered an autoimmune disease.

Clinical study: A research study conducted by investigators to determine the effectiveness and safety of a treatment like IMAAVY. The U.S. Food and Drug Administration, or FDA, reviews clinical trial data to determine if an investigational treatment is safe and effective to be approved for use.

FcRn (neonatal fragment crystallizable receptor) blocker: A class of medications that IMAAVY belongs to. FcRn blockers bind to FcRn, a protein in your body, to help reduce the levels of IgG antibodies, including harmful IgG antibodies.

Food and Drug Administration (FDA): A government agency responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, and the safety of our nation's food supply, cosmetics, and products that emit radiation.

Generalized myasthenia gravis (gMG): The most common form of MG, a rare autoimmune neuromuscular disease that interrupts the communication between the nerves and muscles, causing muscle weakness and tiredness.

Harmful immunoglobulin G (IgG) antibodies: Also known as autoantibodies, they are a type of antibody that attacks the body's own tissues and organs, leading to symptoms such as those seen in autoimmune disorders like gMG. In gMG, these harmful IgG antibodies can include harmful anti-AChR and anti-MuSK antibodies.

Immunoglobulin G (IgG): A type of antibody and the most common type found in the body. They are produced by the immune system to help protect the body from infection and disease.

Intravenous (IV) infusion: A process that delivers fluids or medication directly to the bloodstream through a vein. IMAAVY is given as an IV infusion by your healthcare provider or trained infusion specialist.

Myasthenia gravis (MG): A rare, chronic autoimmune condition that disrupts communication between muscles and nerves.

Neonatal fragment crystallizable receptor (FcRn): A protein that helps regulate the amount of immunoglobulin G (IgG) antibodies circulating through your body. FcRn blockers like IMAAVY bind to this protein in order to help reduce IgG antibody levels.

Neuromuscular junction: A region in your body where the nerves and muscles meet, allowing for signals to be sent between them. MG affects the neuromuscular junction's ability to send these signals.

Receptors: In generalized myasthenia gravis (gMG), receptors refer to proteins at the neuromuscular junction (such as acetylcholine receptor [AChR] and muscle-specific tyrosine kinase [MuSK]) that help nerves communicate with muscles.

Community resources

Gain insights and tips for living with gMG.

Myasthenia Gravis Foundation of America (MGFA) Logo

Myasthenia Gravis Foundation of America (MGFA)

The largest and leading MG advocacy organization in the United States. They are dedicated to finding a cure for MG while improving the lives of people living with it.

MGFA - MG Lexicon

Produced in collaboration with patients, medical professionals, and industry partners, this lexicon guide bridges the gap in terminology between healthcare providers and those affected by MG.

IMAAVY® (nipocalimab-aahu) Transparent LogoIMAAVY® (nipocalimab-aahu) Transparent Logo

Get personalized support tailored
to your unique needs

Once you and your healthcare provider have decided that IMAAVY is
 right for you, IMAAVY withMe is here for you and your loved ones with
free personalized support when and where you may need it.

IMAAVY® (nipocalimab-aahu) Transparent Logo